Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
Clinical trial NCT01998126 · COMPLETED
Trial details
- NCT number
- NCT01998126
- Sponsor
- University of Utah
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2013-12-02
- Primary completion
- 2017-05-09
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.